Cardiac Sympathetic Imaging With mIBG in Heart Failure
Ignasi Carrió, MD*,*,
Martin R. Cowie, MD, MSc ,
Junichi Yamazaki, MD ,
James Udelson, MD||,
Paolo G. Camici, MD*,
* Hospital Sant Pau, Barcelona, Spain
National Heart & Lung Institute, Imperial College, London, United Kingdom
Clinical Sciences Centre, Imperial College, London, United Kingdom
Toho University School of Medicine, Tokyo, Japan
|| Tufts University School of Medicine, Boston, Massachusetts
* Reprint requests and correspondence: Dr. Ignasi Carrió, Hospital Sant Pau, Nuclear Medicine, Pare Claret 167, Barcelona 08025, Spain (Email: icarrio{at}santpau.cat).
Cardiac sympathetic imaging with meta-iodobenzylguanidine (mIBG) is a noninvasive tool to risk stratify patients with heart failure (HF). In patients with ischemic and nonischemic cardiomyopathy, cardiac mIBG activity is a very powerful predictor of survival. Cardiac sympathetic imaging can help in understanding how sympathetic overactivity exerts its deleterious actions, which may result in better therapy and outcome for patients with HF.
Key Words: mIBG heart failure cardiac sympathetic imaging sudden death prognosis
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | BNP = brain natriuretic peptide | | EP = electrophysiology | | HF = heart failure | | HMR = heart-to-mediastinum ratio | | LVEF = left ventricular ejection fraction | | mIBG = meta-iodobenzylguanidine | | MPI = myocardial perfusion imaging | | NE = norepinephrine | | NYHA = New York Heart Association | | SPECT = single-photon emission computed tomography | | WO = wash-out |
|
This article has been cited by other articles:

|
 |

|
 |
 
V. Dilsizian, Y. Chandrashekhar, and J. Narula
Introduction of New Tests: Low Are the Mountains, High the Expectations
J. Am. Coll. Cardiol. Img.,
January 1, 2010;
3(1):
117 - 119.
[Full Text]
[PDF]
|
 |
|
|